Efficacy

Able to finish something satisfactorly

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
AbbVie Brasil
January 21, 2021
www.prnewswire.com:443
- Significativamente, mais pacientes adultos com retocolite ulcerativa grave, tratados com upadacitinibe, alcançaram remissão clínica (desfecho primário, pelo...
Tris Pharma, Inc.
January 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of...
AbbVie
January 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of...
AbbVie
January 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1...
AbbVie
December 11, 2020
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...
AbbVie
December 10, 2020
www.prnewswire.com:443
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved...
December 9, 2020
clinicaltrials.gov
The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 - Full Text View.
December 2, 2020
clinicaltrials.gov
Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans - Full Text View.
November 6, 2020
BioSpace
TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials - read this article along with other careers information, tips and advice on BioSpace
Janssen Pharmaceutical Companies of Johnson & Johnson
November 6, 2020
www.prnewswire.com:443
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2,...
October 22, 2020
clinicaltrials.gov
Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19 - Full Text View.
BioSpace
June 6, 2020
BioSpace
New Analyses Presented at the European Academy of Allergy and Clinical Immunology Digital Congress
BioSpace
June 6, 2020
BioSpace
The safety profile of RINVOQ was consistent with previously reported results in rheumatoid arthritis, with no new risks identified
May 8, 2020
The Lancet
Early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19. Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted.
May 8, 2020
clinicaltrials.gov
Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19 - Full Text View.
April 28, 2020
clinicaltrials.gov
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection - Full Text View.
April 24, 2020
clinicaltrials.gov
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia - Full Text View.
April 17, 2020
clinicaltrials.gov
A Study to Assess the Efficacy and Safety of of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19. - Full Text View.
April 8, 2020
clinicaltrials.gov
Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19 - Full Text View.
AbbVie
April 30, 2019
www.prnewswire.com:443
NORTH CHICAGO, Ill., April 30, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.